EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study

John Whalen, Anita Chandra, Sven Kracker, Stephan Ehl, Markus G Seidel, Ioana Gulas, Louis Dron, Russanthy Velummailum, Chenthila Nagamuthu, Sichen Liu, Joanne Tutein Nolthenius, Maria Elena Maccari

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxae107 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von John Whalen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharming Group N.V., Leiden, The Netherlands. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Immunoglobulin M, Primary Immunodeficiency Diseases, Respiratory Tract Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leniolisib, an oral, targeted phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, was well-tolerated and efficacious versus placebo in treating individuals with activated PI3Kδ syndrome (APDS), an ultra-rare inborn error of immunity (IEI), in a 12-week randomised controlled trial. However, longer-term comparative data versus standard of care are lacking. This externally controlled study compared the long-term effects of leniolisib on annual rate of respiratory tract infections and change in serum immunoglobulin M (IgM) levels versus current standard of care, using data from the leniolisib single-arm open-label extension study 2201E1 (NCT02859727) and the European Society for Immunodeficiencies (ESID) registry. The endpoints were chosen following feasibility assessment considering comparability and availability of data from both sources. Baseline characteristics between groups were balanced through inverse probability of treatment weighting. The leniolisib-treated group included 37 participants, with 62 and 49 participants in the control group for the respiratory tract infections and serum IgM analyses, respectively. Significant reductions in the annual rate of respiratory tract infections (rate ratio: 0.34; 95% confidence interval [CI]: 0.19, 0.59) and serum IgM levels (treatment effect: –1.09 g/L; 95% CI: –1.78, –0.39, P = 0.002) were observed in leniolisib-treated individuals versus standard of care. The results were consistent across all sensitivity analyses, regardless of censoring, baseline infection rate definition, missing data handling, or covariate selection. These novel data provide an extended comparison of leniolisib treatment versus standard of care, highlighting the potential for leniolisib to deliver long-term benefits by restoring immune system function and reducing infection rate, potentially reducing complications and treatment burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesImmunoglobulin MPrimary Immunodeficiency DiseasesRespiratory Tract InfectionsAdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultStandard of CareTreatment OutcomeObservational Studies as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

APDSESIDPI3Kδimmunoglobulininfectionleniolisib

Substanzen

Class I Phosphatidylinositol 3-KinasesImmunoglobulin M

Autor:innen und Institutionen

  • Pharming Group N.V., Leiden, The Netherlands.
  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Université Paris Cité, Imagine Institute, Laboratory of Human Lymphohematopoiesis, INSERM UMR 1163, F-7015, Paris, France.
  • Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Division of Pediatric Hematology Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria.
  • Cytel Inc., Toronto, Ontario, Canada.

Zitieren

APA

Whalen, J., Chandra, A., Kracker, S., Ehl, S., Seidel, M. G., Gulas, I., Dron, L., Velummailum, R., Nagamuthu, C., Liu, S., Tutein Nolthenius, J., & Maccari, M. E. (2025). Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae107

Vancouver

Whalen J, Chandra A, Kracker S, Ehl S, Seidel MG, Gulas I, et al. Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae107

BibTeX
@article{Whalen2025,
  author = {Whalen, John and Chandra, Anita and Kracker, Sven and Ehl, Stephan and Seidel, Markus G and Gulas, Ioana and Dron, Louis and Velummailum, Russanthy and Nagamuthu, Chenthila and Liu, Sichen and Tutein Nolthenius, Joanne and Maccari, Maria Elena},
  title = {Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxae107}
}
Kostenlos starten →